Condition
Relapsed/Refractory Multiple Myeloma(MM)
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Recruiting2
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07100067Not ApplicableRecruitingPrimary
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
NCT07139509Phase 1RecruitingPrimary
Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma
NCT03473496Not ApplicableTerminatedPrimary
CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
Showing all 3 trials